畅联股份：与上海外高桥生物医药设立合资公司并完成协议签署

Core Viewpoint - Changlian Co., Ltd. (603648.SH) has signed an investment agreement with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd. to establish Shanghai Changlian Baifu Pharmaceutical Co., Ltd. [1] Group 1 - Changlian Co., Ltd. will invest 30 million yuan, accounting for 60% of the registered capital of the new company [1] - The registered capital of the new company is set at 50 million yuan, with a profit distribution ratio of no less than 60% of the annual net profit [1] - The investment is expected to be completed by January 30, 2026 [1]